Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Natalizumab Re-Initiation of Dosing

ClinicalTrials.gov ID: NCT00306592

Public ClinicalTrials.gov record NCT00306592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 3, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation

Study identification

NCT ID
NCT00306592
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Biogen
Industry
Enrollment
404 participants

Conditions and interventions

Interventions

  • BG00002 (natalizumab) Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Nov 30, 2007
Completion
Jan 31, 2008
Last update posted
Mar 20, 2017

2006 – 2008

United States locations

U.S. sites
53
U.S. states
28
U.S. cities
49
Facility City State ZIP Site status
Research Site Birmingham Alabama 35233
Research Site Phoenix Arizona 85006
Research Site Scottsdale Arizona 85259
Research Site Little Rock Arkansas 72205
Research Site Berkeley California 94705
Research Site Los Angeles California 90033
Research Site Redwood City California 94063
Research Site Sacramento California 95817
Research Site San Francisco California 94117
Research Site Colorado Springs Colorado 80919
Research Site New Haven Connecticut 06510
Research Site Washington D.C. District of Columbia 20007
Research Site Maitland Florida 32751
Research Site Miami Florida 33136
Research Site Pompano Beach Florida 33060
Research Site Atlanta Georgia 30327
Research Site Arlington Illinois 60007
Research Site Chicago Illinois 60612
Research Site Chicago Illinois 60637
Research Site Northbrook Illinois 60062
Research Site Des Moines Iowa 50314
Research Site Kansas City Kansas 66160
Research Site Baltimore Maryland 21201
Research Site Worcester Massachusetts 01655
Research Site East Lansing Michigan 48824
Research Site Farmington Hills Michigan 48334
Research Site Teaneck New Jersey 07666
Research Site Albuquerque New Mexico 87131
Research Site Albany New York 12208
Research Site Buffalo New York 14203
Research Site Great Neck New York 10019
Research Site New York New York 10003
Research Site New York New York 10319
Research Site Staten Island New York 10305
Research Site Syracuse New York 13202
Research Site Charlotte North Carolina 28207
Research Site Raleigh North Carolina 27607
Research Site Fargo North Dakota 58103
Research Site Cincinnati Ohio 45219
Research Site Cleveland Ohio 44195
Research Site Portland Oregon 97225
Research Site Allentown Pennsylvania 18103
Research Site Philadelphia Pennsylvania 19104
Research Site Philadelphia Pennsylvania 19146
Research Site Pittsburgh Pennsylvania 15212
Research Site Pittsburgh Pennsylvania 15213
Research Site Memphis Tennessee 38163
Research Site Nashville Tennessee 37215
Research Site Dallas Texas 75214
Research Site Round Rock Texas 78681
Research Site Burlington Vermont 05401
Research Site Charlottesville Virginia 22903
Research Site Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00306592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 20, 2017 · Synced May 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00306592 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →